SuperworthLiquidia LQDA
- Market cap
- $3.8B
- PE
- 30.7×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 8.5×
- EV/EBIT
- 21.7×
- Revenue, 12 months
- $450.9M
- growth n/m, growth from a base too small to compare
- Net margin
- 30.7%
- Free cash flow yield
- 3.9%
Liquidia trades at 30.7× trailing earnings. Revenue was $450.9M over the last twelve months with a 31% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $3.7M+16% | $4.5M−16% | $3M−34% | $3.7M−24% | $4.4M+21% | $2.9M−36% | $3.1M+5% | $8.8M+142% | $54.3M+1122% | $92M+3055% | $132.9M+4159% | $171.7M+1843% | |
| Cost of revenue | $570K−23% | $993K+43% | $1.5M+124% | $1.5M+123% | $1.6M+175% | $1.4M+36% | $1.5M+3% | $1.5M+0% | $3.2M+103% | $7.1M+421% | $11.9M+681% | $11.6M+672% |
| Gross profit | $3.1M+28% | $3.5M−24% | $1.5M−61% | $2.2M−47% | $2.9M−7% | $1.6M−56% | $1.6M+7% | $7.3M+239% | $51.2M+1675% | $85M+5336% | $121M+7449% | $160.1M+2082% |
| R&D | $7.4M+65% | $12.8M+158% | $10.1M+91% | $9.4M−47% | $11.9M+60% | $16.5M+28% | $7M−31% | $6M−36% | $9.3M−21% | $16.9M+3% | $12.6M+81% | $17.2M+185% |
| SG&A | $10.6M+57% | $17.1M+177% | $20.2M+160% | $19.9M+116% | $20.2M+91% | $21.2M+24% | $30.1M+49% | $38.8M+95% | $40.1M+99% | $48.2M+128% | $46.9M+56% | $57.4M+48% |
| −$14.9M+69% | −$26.4M+307% | −$28.8M+212% | −$27.2M+19% | −$29.2M+96% | −$36.1M+37% | −$35.4M+23% | −$37.5M+38% | $1.8M | $19.8M | $61.5M | $85.5M | |
| Interest expense | $1.8M+184% | $2M+181% | $3.2M+181% | $3.3M+133% | $3.7M+108% | $4.5M+130% | $4.7M+48% | $5.7M+70% | $6.9M+90% | $6.9M+53% | $6.5M+39% | $6.3M+11% |
| Pre-tax income | n/a | n/a | n/a | n/a | n/a | n/a | −$38.4M | −$41.6M | n/a | n/a | $56.8M | $81.7M |
| n/a | n/a | n/a | n/a | n/a | n/a | $0 | $0 | n/a | n/a | $3.9M | $7M | |
| Net income | −$15.8M+74% | −$27.4M+320% | −$30.1M+156% | −$28.7M+22% | −$31M+97% | −$38.5M+40% | −$38.4M+28% | −$41.6M+45% | −$3.5M−89% | $14.6M | $52.9M | $74.7M |
| −$0.24+71% | −$0.42+320% | −$0.40+122% | −$0.38+6% | −$0.40+67% | −$0.46+10% | −$0.45+13% | −$0.49+29% | −$0.04−90% | $0.17 | $0.52 | $0.74 | |
| 64.9M+1% | 65.7M+2% | 75.4M+17% | 76.4M+18% | 78.3M+21% | 84.6M+29% | 85.2M+13% | 85.6M+12% | 86.3M+10% | 87.1M+3% | 101.1M+19% | 101.4M+19% |
Revenue: Q1 FY17 and Q1 FY18: 6 months less the 3 months printed beside them.
Cost of revenue: Q1 FY17 and Q1 FY18: 6 months less the 3 months printed beside them.
Gross profit: Q1 FY17 and Q1 FY18: 6 months less the 3 months printed beside them. 35 periods, Q2 FY17 to Q2 FY26: not printed by the filing, worked out from its own lines.
R&D: Q1 FY17: 6 months less the 3 months printed beside them.
SG&A: Q1 FY17 and Q1 FY18: 6 months less the 3 months printed beside them.
Operating income: Q1 FY17: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY17: 6 months less the 3 months printed beside them.
Net income: Q1 FY17 and Q1 FY18: 6 months less the 3 months printed beside them.
EPS, diluted: 10 periods, Q1 FY17 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY17: share-days: the 6-month average less the second quarter's. Q4 FY17 and Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days. 7 periods, Q4 FY18 to Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Liquidia's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| LQDALiquidia | $3.8B | 30.7× | 53.6× | 8.5× | n/m | 30.7% | |
| ARQTArcutis Biotherapeutics | $3.9B | 142× | 115× | 8.5× | +76% | 6.1% | |
| OGNOrganon | $3.6B | 17.9× | 5.9× | 0.6× | −2% | 3.4% | |
| INDVIndivior Pharmaceuticals | $4.1B | 12.4× | 20.1× | 3.1× | +13% | 26.7% | |
| NRIXNurix Therapeutics | $2.8B | 11.0× | 10.8× | 3.9× | n/m | 42.0% | |
| KNSAKiniksa Pharmaceuticals International | $6B | 79.1× | 85.3× | 7.1× | +59% | 9.6% | |
| LGNDLigand Pharmaceuticals | $6.1B | 32.3× | 37.7× | 20.8× | +55% | 67.9% | |
| PBHPrestige Consumer Healthcare | $2.3B | 13.4× | 15.3× | 2.0× | −1% | 15.6% | |
| AMRXAmneal Pharmaceuticals | $6.5B | 41.6× | 51.5× | 2.1× | +9% | 5.0% | |
| HRMYHarmony Biosciences | $2.1B | 11.7× | 13.8× | 2.2× | +24% | 18.9% | |
| ALKSAlkermes plc. | $7.3B | 115× | 16.0× | 4.4× | +11% | 4.0% | |
| Peer median | $4B | 25.1× | 18.0× | 3.5× | +13% | 12.6% |
More on Liquidia
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .